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Abstract
Recent advances in the field of colorectal cancer screening have led to updated guidelines from
several national societies. Although various strategies have been illustrated to reduce mortality from
colorectal cancer, screening tests differ in their ability to detect neoplasia. While this is an issue for all
lesions, it is a particular problem for non-polypoid or ‘flat’ colonic neoplasia, which has been
recognized to be prevalent in Western countries. Guidelines also recommend the age at which
screening is initiated and discontinued; however, emerging data suggest these thresholds may lead to
missed lesions. Finally, evidence points to disparities in the availability and utilization of colorectal
cancer screening tests, which may be successfully addressed through interventions that educate both
patients and their providers. The focus of future efforts includes increasing adherence to
recommended screening strategies.
Introduction and context
The availability of new colorectal cancer screening
(CRCS) modalities, including computed tomography
(CT) colonography, fecal DNA testing and capsule
colonoscopy, has rejuvenated interest in this topic,
culminating in the publication of two updated guide-
lines for CRCS this year. Despite the availability of
similar data for review, these societal guidelines arrived
at different conclusions regarding recommended strate-
gies. In March 2008 the American Cancer Society, the US
Multi-Society Task Force on Colorectal Cancer (including
the major US national gastroenterology societies) and
the American College of Radiology jointly published
their guidelines [1]. These guidelines offer a menu of
options that include flexible sigmoidoscopy every
5 years, colonoscopy every 10 years, double-contrast
barium enema every 5 years, computed tomographic
colonography (virtual colonoscopy) every 5 years,
annual ‘sensitive’ fecal occult blood testing (FOBT)
using highly sensitive guaiac or fecal immunochemical
testing, or stool DNA testing. However, it was strongly
recommended CRCS be conducted with strategies that
detect adenomatous polyps in addition to early cancer.
This recommendation includes CT colonography, which
has not been shown to reduce colorectal cancer incidence
or mortality.
Subsequently, the US Preventive Services Task Force
(USPSTF) published their recommendations for CRCS,
in which the decisions to include strategies were based
on evidence of reductions in mortality from colorectal
cancer [2]. Based on these criteria, they approved
screening with FOBT, flexible sigmoidoscopy or colono-
scopy. FOBT has high-quality evidence to support
reductions in colorectal cancer mortality from multiple
randomized controlled clinical trials [3–5]. Colonoscopy
and flexible sigmoidoscopy have been demonstrated to
achieve mortality benefit through retrospective case-
control and prospective cohort studies with historical
controls [6–9]. CT colonography, barium enema and
fecal DNA testing were not recommended, based on the
lack of data to determine whether they improve clinical
outcomes. It also remains to be seen whether the results
achieved in the context of clinical trials can be replicated
in the community practice setting, where variation in
procedure performance may impact the goals of cancer
mortality reduction.
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on whether existing evidence supports reduction in
colorectal cancer mortality (USPSTF) or whether com-
parison of newer methods with colonoscopy to detect
colonic lesions is sufficient to include a recommendation
(Multi-Society Task Force). With the backdrop of these
conflicting guidelines, substantial issues were raised in
the past year through publications that addressed factors
that impact the outcomes achievable through competing
CRCS strategies.
Recent advances
Flat adenomas
One of the advances in CRCS was the finding that ‘flat
polyps’ were prevalent among United States residents.
These lesions were previously believed to be limited to
people in Asian countries. A study by Soetikno et al. [10]
revealed that flat, otherwise known as non-polypoid,
colorectal neoplasia was present in 9% of the screening
population, and up to 15% of patients with a prior
history of colonic neoplasia. While the prevalence of
in situ or invasive cancer was less than 1%, they were
more likely to occur in non-polypoid compared to
traditional polypoid lesions. Moreover, an astounding
33% of ‘depressed’ non-polypoid lesions were malig-
nant. The clinical implications of these findings are that
certain screening modalities such as CT or magnetic
resonance colonography (virtual colonoscopy) are less
likely to identify flat lesions, which may limit their
applicability for CRCS.
The clinical relevance of small lesions with regards to
their risk of progression to malignancy was further
addressed by Lieberman et al. [11] through analysis of
almost 14,000 patients who had undergone screening
colonoscopy. The outcome of interest was the prevalence
of ‘advanced histology’, defined as an adenoma with
villous or serrated histology, high-grade dysplasia or an
invasive cancer. While the proportion of polyps >10 mm
harboring advanced histology was 30.6%, 6.6% of
polyps within the 6–9 mm range and 1.7% of polyps
1–5 mm in diameter also possessed advanced histology.
These findings impact indirect imaging methods such as
virtual colonoscopy, since even among experienced
radiologists CT colonography has a sensitivity of 88%
for 6 mm lesions [12]. Using current recommendations,
patients with lesions <10 mm in diameter diagnosed by
CT colonography would not necessarily undergo
immediate polypectomy. It has been suggested that
they instead be followed by surveillance colonography.
Additionally, it has been advised that lesions <5 mm in
diameter diagnosed by CT not be reported [13].
Although the proportion of small lesions having
advanced histology is small, the prevalence of small
lesions is high. However, the importance and clinical
implications of not removing these lesions with respect
to the ability of virtual colonoscopy to reduce colorectal
cancer mortality is unknown.
Age to initiate and cease CRCS
Published guidelines recommend initiation of CRCS for
patients at average risk for development of cancer at age
50 years. There is an exception from the American
College of Gastroenterology guidelines [14] that recom-
mends beginning screening at age 45 years among
African-Americans based on epidemiological data [15].
The greater question is whether these age thresholds are
valid for any group regardless of racial categorization.
Rundle et al. [16] analyzed 905 colonoscopies performed
for screening on average-risk persons from 40–59 years
of age and reported no difference in the proportion
diagnosed with colonic adenomas between those 40–49
years of age (14%) and those 50–59 years of age (16%).
While there was a trend towards an increase in the
proportion of persons with advanced adenomas among
those 50–59 years of age (4%) compared to those 40–49
years of age (2%), this difference was not statistically
different. Thus, while it is known that the incidence of
cancer is lower for persons younger than 50 years of age,
it appears that if the goals of screening are to detect and
remove adenomas, perhaps initiation of screening at an
age earlier than 50 years is reasonable. The economic
impact of lowering the age at which to initiate screening,
however, is unknown.
An equally contentious issue is the age at which to cease
screening. The USPSTF recommends discontinuation of
screening of average risk persons after the age of 75 years
[2]. The rationale for this recommendation is that while
the incidence of, and mortality from, colorectal cancer
continue to increase with age, so does the risk of
mortality from competing disease. However, these
recommendations are not based on solid data; thus,
from health quality and economic perspectives, recom-
mendations regarding the age at which to stop screening
remain fluid.
Adherence to colorectal cancer screening
Finally, the most important question regarding choice of
CRCS strategies may not revolve around which is most
effective but rather to which strategy will patients more
often adhere? Several studies have been published this
past year focusing on issues of adherence to CRCS tests.
McAlearney et al. [17] conducted face-to-face interviews
with 941 women older than 50 years of age who were
living in subsidized housing in selected Southern
communities. While adherence to CRCS was reported
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American women were half as likely as white women to
report having undergone screening by colonoscopy. In
conjunction with this disparity was awareness of
different tests for CRCS, which was significantly lower
among African-Americans than whites. Correspondingly,
there was a similar significant difference in lack of
insurance coverage between African-Americans and
whites. Disparities in the rate of CRCS also exist among
non-black minorities, with reduced rates in Asians and
Hispanics [18,19]. Furthermore, use of colonoscopy
among those persons who are screened is particularly
deficient among non-white populations [20]. This
evidence points to the need for greater awareness and
availability of CRCS focused specifically on populations
vulnerable to disparities based on racial or socioeco-
nomic factors.
In order to address these disparities in health care
utilization, another group of investigators tested a novel
intervention using computer-assisted patient teaching
and tailored written recommendations in rural primary
care practices to improve communication and discussion
about CRCS [21]. In clinics exposed to this intervention,
providers and patients discussed CRCS more often,
providers more often recommended CRCS, and patients
described a higher intention to be screened than in
clinics not exposed to the intervention. Thus, it appears
that some of the deficits based on socioeconomic factors
may be overcomethrough the use of new technology and
techniques for disseminating information among
patients and their providers. It should be realized,
however, that other significant barriers remain based
on access to primary and specialty care, insurance,
acculturation and language. Capacity limitations of
colonoscopy and the unequal distribution of capacity
also impacts access to CRCS. Finally, variation among
physicians with regards to the level of recommendation
to undergo screening may constitute a target for reducing
disparities in CRCS.
Implications for clinical practice
Recently published guidelines differ with regards to
recommended strategies to reduce mortality from color-
ectal cancer. The differences stem from the level of
evidence from clinical studies required by the societies
for inclusion of screening modalities. The USPSTF
recommendations, which are based on more rigorous
criteria requiring evidence for improvement in colorectal
cancer mortality support FOBT, flexible sigmoidoscopy
and colonoscopy as screening tests. The Multi-Society
Task Force included CT colonography and fecal DNA
testing based on comparative studies using colonoscopy
as the gold standard for detection of colonic lesions.
From a clinical perspective, reports of a substantial
prevalence of non-polypoid lesions in the US reduce the
viability of strategies that do not directly visualize the
colonic mucosa. Practically speaking, however, the limit
to adoption of CT colonography and fecal DNA testing
may be more linked to reimbursement for use of these
technologies for CRCS rather than the level of evidence
supporting their use.
Regardless of the efficacy of competing strategies to
reduce mortality from CRC, the more important issue
may be whether patients adhere to any form of CRCS.
Recent evidence illustrates significant disparities in the
availability and utilization of CRCS tests based on racial/
ethnic or socioeconomic factors. Additional studies,
however, have demonstrated that specific educational
interventions can improve the acceptability of CRCS tests
and may ultimately increase overall adherence to CRCS
strategies. The key issue to improve the health of
populations may not be to determine the most
efficacious test, but rather to identify to which CRCS
test a particular patient is most likely to adhere.
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